We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?
Read MoreHide Full Article
Key Takeaways
Ironwood expects strong Linzess demand to drive higher profit contributions in Q3 2026.
Linzess prescription demand surged in 1H 2026, lifting IRWD's U.S. net profit share 72.6% year over year.
IRWD raised 2026 revenue guidance to $460-$485 million, reflecting strong Linzess demand in the first half.
Ironwood Pharmaceuticals’ (IRWD - Free Report) sole marketed product, Linzess (linaclotide), is witnessing strong prescription demand and uptake in recent times. The company has a partnership with drug giant AbbVie (ABBV - Free Report) to jointly develop and commercialize Linzess in the United States.
Ironwood’s top line primarily comprises revenues recorded through its collaborative arrangements with ABBV related to the development and commercialization of Linzess in the United States.
IRWD and ABBV equally share Linzess’ brand collaboration profits and losses in the country.
Linzess is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged seven years and above. The drug is also approved for treating functional constipation (FC) in children and adolescents aged six to 17 years.
The recent FDA approval expanding Linzess’ use in pediatric patients with FC should provide an additional opportunity to support sales growth.
Given the lack of FDA-approved prescription pediatric therapies for FC, these expanded approvals create a meaningful growth opportunity for Ironwood. As the company gears up to report its third-quarter results, investors are likely to keep a close eye on Linzess’ sales performance.
Ironwood also has agreements with Astellas Pharma and AstraZeneca (AZN - Free Report) related to the development and commercialization of Linzess in Japan and China, respectively.
Both Astellas Pharma and AstraZeneca pay royalties to Ironwood on net Linzess revenues earned in their regions. These partnerships provide Ironwood with an additional revenue stream through royalties on Linzess sales outside the United States.
IRWD Banks on Linzess to Aid Sales
Importantly, earlier this year, Linzess' list price was reduced to support patient access. Despite the reduction, management expects Linzess' net sales to grow year over year through 2026, as the lower list price should reduce certain mandatory government rebates.
As a result, lower rebate payments are expected to drive higher net revenues in 2026.
Linzess sales have witnessed a strong surge in the first half of 2026, subsequently boosting Ironwood’s share of net profits from sales of the partnered drug in the United States. Ironwood’s share of net profit from the sales of Linzess in the United States surged 72.6% year over year during the first six months of 2026.
Management expects the prescription demand momentum to persist, with mid-single-digit demand growth anticipated for full-year 2026.
Reflecting the strong first-half performance and continued demand for Linzess, Ironwood raised its 2026 total revenue guidance to $460-$485 million, up from $450-$475 million previously.
Continued prescription demand, the recent label expansion and favorable pricing dynamics should support higher profit contributions from Linzess in the third quarter.
IRWD's Price Performance, Valuation and Estimates
Year to date, Ironwood shares have risen 7.7% while the industry has declined 5.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, Ironwood is trading at a discount to the industry. Going by the price-to-sales ratio, the company’s shares currently trade at 1.56, lower than 19.82 for the industry. The stock is also trading below its five-year mean of 3.06.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share has increased from $1.04 to $1.10 over the past 60 days. During the same time frame, loss per share estimates for 2027 have remained stable at 3 cents.
View the Zacks #1 Rank List
Image: Bigstock
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?
Key Takeaways
Ironwood Pharmaceuticals’ (IRWD - Free Report) sole marketed product, Linzess (linaclotide), is witnessing strong prescription demand and uptake in recent times. The company has a partnership with drug giant AbbVie (ABBV - Free Report) to jointly develop and commercialize Linzess in the United States.
Ironwood’s top line primarily comprises revenues recorded through its collaborative arrangements with ABBV related to the development and commercialization of Linzess in the United States.
IRWD and ABBV equally share Linzess’ brand collaboration profits and losses in the country.
Linzess is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged seven years and above. The drug is also approved for treating functional constipation (FC) in children and adolescents aged six to 17 years.
The recent FDA approval expanding Linzess’ use in pediatric patients with FC should provide an additional opportunity to support sales growth.
Given the lack of FDA-approved prescription pediatric therapies for FC, these expanded approvals create a meaningful growth opportunity for Ironwood. As the company gears up to report its third-quarter results, investors are likely to keep a close eye on Linzess’ sales performance.
Ironwood also has agreements with Astellas Pharma and AstraZeneca (AZN - Free Report) related to the development and commercialization of Linzess in Japan and China, respectively.
Both Astellas Pharma and AstraZeneca pay royalties to Ironwood on net Linzess revenues earned in their regions. These partnerships provide Ironwood with an additional revenue stream through royalties on Linzess sales outside the United States.
IRWD Banks on Linzess to Aid Sales
Importantly, earlier this year, Linzess' list price was reduced to support patient access. Despite the reduction, management expects Linzess' net sales to grow year over year through 2026, as the lower list price should reduce certain mandatory government rebates.
As a result, lower rebate payments are expected to drive higher net revenues in 2026.
Linzess sales have witnessed a strong surge in the first half of 2026, subsequently boosting Ironwood’s share of net profits from sales of the partnered drug in the United States. Ironwood’s share of net profit from the sales of Linzess in the United States surged 72.6% year over year during the first six months of 2026.
Management expects the prescription demand momentum to persist, with mid-single-digit demand growth anticipated for full-year 2026.
Reflecting the strong first-half performance and continued demand for Linzess, Ironwood raised its 2026 total revenue guidance to $460-$485 million, up from $450-$475 million previously.
Continued prescription demand, the recent label expansion and favorable pricing dynamics should support higher profit contributions from Linzess in the third quarter.
IRWD's Price Performance, Valuation and Estimates
Year to date, Ironwood shares have risen 7.7% while the industry has declined 5.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, Ironwood is trading at a discount to the industry. Going by the price-to-sales ratio, the company’s shares currently trade at 1.56, lower than 19.82 for the industry. The stock is also trading below its five-year mean of 3.06.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share has increased from $1.04 to $1.10 over the past 60 days. During the same time frame, loss per share estimates for 2027 have remained stable at 3 cents.
Image Source: Zacks Investment Research
IRWD's Zacks Rank
Ironwood currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.